CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
EKF Diagnostics offers a novel test to accurately identify diabetic patients at high risk of progression to end-stage renal disease (ESRD) up to 10 years before currently available tests can. EKF’s sTNFr1 test is an ELISA assay that has the potential to significantly improve diabetic patient management and outcomes.
The test accurately detects circulating levels of soluble tumor necrosis factor receptor 1 (sTNFr1) in patient samples. Research has demonstrated that high circulating levels of sTNFr1 are strongly associated with progression to ESRD in patients with and without overt nephropathy.
The sTNFr1 test is an easy-to-use plate assay that requires minimal training. As an ELISA-based assay, standard laboratory equipment can be used to analyze 50 µL of blood serum or plasma. The assay uses monoclonal antibodies to provide accurate and reliable results in a few hours. Furthermore, it has minimal interference and does not cross-react with sTNFr2.
EKF Diagnostics, 800-531-5535